118 related articles for article (PubMed ID: 38453679)
1. Prognostic relevance of the C-X-C motif chemokine ligand 13 and interleukin-8 in predicting the transition from clinically isolated syndrome to multiple sclerosis.
Klíčová K; Mareš J; Sobek O; Rous Z; Rous M; Raška M; Hartung HP
Eur J Neurosci; 2024 Jun; 59(11):2955-2966. PubMed ID: 38453679
[TBL] [Abstract][Full Text] [Related]
2. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
[TBL] [Abstract][Full Text] [Related]
4. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS.
Sellebjerg F; Börnsen L; Khademi M; Krakauer M; Olsson T; Frederiksen JL; Sørensen PS
Neurology; 2009 Dec; 73(23):2003-10. PubMed ID: 19996075
[TBL] [Abstract][Full Text] [Related]
5. Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis.
Ahlbrecht J; Martino F; Pul R; Skripuletz T; Sühs KW; Schauerte C; Yildiz Ö; Trebst C; Tasto L; Thum S; Pfanne A; Roesler R; Lauda F; Hecker M; Zettl UK; Tumani H; Thum T; Stangel M
Mult Scler; 2016 Aug; 22(9):1202-14. PubMed ID: 26493127
[TBL] [Abstract][Full Text] [Related]
6. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS).
Brettschneider J; Czerwoniak A; Senel M; Fang L; Kassubek J; Pinkhardt E; Lauda F; Kapfer T; Jesse S; Lehmensiek V; Ludolph AC; Otto M; Tumani H
PLoS One; 2010 Aug; 5(8):e11986. PubMed ID: 20700489
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid neurofilament light chains and CXCL13 as predictive factors for clinical course of multiple sclerosis.
Hradilek P; Revendova KZ; Horakova J; Bunganic R; Pelisek O; Zeman D; Hanzlikova P; Kusnierova P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2023 Mar; 167(1):30-35. PubMed ID: 36695545
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.
Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
J Neurochem; 2017 Apr; 141(2):296-304. PubMed ID: 27787906
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome.
Thouvenot E; Hinsinger G; Demattei C; Uygunoglu U; Castelnovo G; Pittion-Vouyovitch S; Okuda D; Kantarci O; Pelletier D; Lehmann S; Marin P; Siva A; Lebrun C
Mult Scler; 2019 Apr; 25(5):669-677. PubMed ID: 29564952
[TBL] [Abstract][Full Text] [Related]
10. BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset.
Puthenparampil M; Federle L; Miante S; Zito A; Toffanin E; Ruggero S; Ermani M; Pravato S; Poggiali D; Perini P; Rinaldi F; Gallo P
J Neuroinflammation; 2017 Jan; 14(1):11. PubMed ID: 28095856
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation.
Bielekova B; Komori M; Xu Q; Reich DS; Wu T
PLoS One; 2012; 7(11):e48370. PubMed ID: 23226202
[TBL] [Abstract][Full Text] [Related]
12. CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis.
Tumani H; Lehmensiek V; Rau D; Guttmann I; Tauscher G; Mogel H; Palm C; Hirt V; Suessmuth SD; Sapunova-Meier I; Ludolph AC; Brettschneider J
Neurosci Lett; 2009 Mar; 452(2):214-7. PubMed ID: 19383442
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: Association with oligoclonal IgM bands and prediction of Multiple Sclerosis diagnosis.
Ferraro D; Galli V; Vitetta F; Simone AM; Bedin R; Del Giovane C; Morselli F; Filippini MM; Nichelli PF; Sola P
J Neuroimmunol; 2015 Jun; 283():64-9. PubMed ID: 26004159
[TBL] [Abstract][Full Text] [Related]
14. CSF levels of HoxB3 and YKL-40 may predict conversion from clinically isolated syndrome to relapsing remitting multiple sclerosis.
Tamam Y; Gunes B; Akbayir E; Kizilay T; Karaaslan Z; Koral G; Duzel B; Kucukali CI; Gunduz T; Kurtuncu M; Yilmaz V; Tuzun E; Turkoglu R
Mult Scler Relat Disord; 2021 Feb; 48():102697. PubMed ID: 33352356
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-12p40 in the spinal fluid as a biomarker for clinically isolated syndrome.
Orbach R; Gurevich M; Achiron A
Mult Scler; 2014 Jan; 20(1):35-42. PubMed ID: 23722323
[TBL] [Abstract][Full Text] [Related]
16. Multiple sclerosis risk genotypes correlate with an elevated cerebrospinal fluid level of the suggested prognostic marker CXCL13.
Lindén M; Khademi M; Lima Bomfim I; Piehl F; Jagodic M; Kockum I; Olsson T
Mult Scler; 2013 Jun; 19(7):863-70. PubMed ID: 23175382
[TBL] [Abstract][Full Text] [Related]
17. The predictive value of CSF multiple assay in multiple sclerosis: A single center experience.
De Fino C; Lucchini M; Lucchetti D; Nociti V; Losavio FA; Bianco A; Colella F; Ricciardi-Tenore C; Sgambato A; Mirabella M
Mult Scler Relat Disord; 2019 Oct; 35():176-181. PubMed ID: 31394405
[TBL] [Abstract][Full Text] [Related]
18. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis.
Martínez MA; Olsson B; Bau L; Matas E; Cobo Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
Mult Scler; 2015 Apr; 21(5):550-61. PubMed ID: 25732842
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.
Khademi M; Kockum I; Andersson ML; Iacobaeus E; Brundin L; Sellebjerg F; Hillert J; Piehl F; Olsson T
Mult Scler; 2011 Mar; 17(3):335-43. PubMed ID: 21135023
[TBL] [Abstract][Full Text] [Related]
20. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis.
Brettschneider J; Petzold A; Junker A; Tumani H
Mult Scler; 2006 Apr; 12(2):143-8. PubMed ID: 16629417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
